CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Cash & Equivalents data on file, last reported at $423.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 79.99% year-over-year to $423.3 million; the trailing twelve-month figure through Mar 2026 stood at $423.3 million (up 79.99% YoY), and the FY2025 full-year result was $347.6 million, changed N/A from the prior year.
• Cash & Equivalents improved to $423.3 million in Q1 2026, from $347.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $707.4 million in Q1 2024 to a low of $193.6 million in Q2 2025.
• A 5-year average of $406.1 million and a median of $406.4 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 77.04% in 2022 and jumped 105.4% in 2024, its largest moves.
• Tracing CRSP's Cash & Equivalents over 5 years: stood at $211.9 million in 2022, then surged by 83.82% to $389.5 million in 2023, then plunged by 42.06% to $225.7 million in 2024, then soared by 54.01% to $347.6 million in 2025, then rose by 21.79% to $423.3 million in 2026.
• Business Quant data shows CRSP's Cash & Equivalents at $423.3 million in Q1 2026, $347.6 million in Q4 2025, and $286.5 million in Q3 2025.